Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
Virginia Tech
mi
from
Blacksburg, VA
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
Virginia Tech
mi
from
Blacksburg, VA
Click here to add this to my saved trials
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated:  6/15/2017
West Virginia University
mi
from
Morgantown, WV
Faith-Based Initiative to Promote Health in Appalachia
Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia
Status: Enrolling
Updated: 6/15/2017
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)
Status: Enrolling
Updated:  6/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)
Status: Enrolling
Updated: 6/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)
Status: Enrolling
Updated:  6/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)
Status: Enrolling
Updated: 6/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Genetic Evaluation of Families With Endocrine Cancers
A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers
Status: Enrolling
Updated:  6/15/2017
Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Genetic Evaluation of Families With Endocrine Cancers
A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers
Status: Enrolling
Updated: 6/15/2017
Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Click here to add this to my saved trials
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients With Esophageal Cancer
Status: Enrolling
Updated:  6/19/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients With Esophageal Cancer
Status: Enrolling
Updated: 6/19/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dexamethasone Dyspnea Study
A Preliminary Study of Dexamethasone for Dyspnea in Cancer Patients
Status: Enrolling
Updated:  6/19/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dexamethasone Dyspnea Study
A Preliminary Study of Dexamethasone for Dyspnea in Cancer Patients
Status: Enrolling
Updated: 6/19/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Status: Enrolling
Updated:  6/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
Status: Enrolling
Updated: 6/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
A Phase I Study of Sirolimus in Combination With Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults With Relapsed and Refractory Solid Tumors
Status: Enrolling
Updated:  6/20/2017
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
A Phase I Study of Sirolimus in Combination With Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults With Relapsed and Refractory Solid Tumors
Status: Enrolling
Updated: 6/20/2017
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Breast Cup Immobilization Device II (GCC 1047)
Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II
Status: Enrolling
Updated:  6/20/2017
Ummc Msgcc
mi
from
Baltimore, MD
Breast Cup Immobilization Device II (GCC 1047)
Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II
Status: Enrolling
Updated: 6/20/2017
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Translational Genomics Research Institute (TGen)
mi
from
Scottsdale, AZ
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Translational Genomics Research Institute (TGen)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Institute of Urologic Oncology
mi
from
Los Angeles, CA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Institute of Urologic Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Stanford University
mi
from
Stanford, CA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Aurora, CO
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
mi
from
Tampa, FL
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
mi
from
Beech Grove, IN
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
mi
from
Beech Grove, IN
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Wichita, KA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Medical Oncology LLC
mi
from
Baton Rouge, LA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Medical Oncology LLC
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC
mi
from
Metairie, LA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC
mi
from
Metairie, LA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Associates in Oncology and Hematology
mi
from
Rockville, MD
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Tupelo, MS
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Las Vegas, NV
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Lebanon, NH
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Columbus, OH
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
OU Cancer Institute
mi
from
Oklahoma City, OK
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
OU Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Austin, TX
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Coastal Bend Cancer Center
mi
from
Corpus Christi, TX
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Coastal Bend Cancer Center
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Dallas, TX
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
Clinical Research Facility
mi
from
Tacoma, WA
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated:  6/20/2017
mi
from
Hamilton,
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Status: Enrolling
Updated: 6/20/2017
mi
from
Hamilton,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  6/21/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 6/21/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
Phase I/ II Trial of Carboplatin and Etoposide Plus LBH589 for Previously Untreated Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  6/21/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
Phase I/ II Trial of Carboplatin and Etoposide Plus LBH589 for Previously Untreated Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 6/21/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
Status: Enrolling
Updated:  6/21/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
Status: Enrolling
Updated: 6/21/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/21/2017
Yale University
mi
from
New Haven, CT
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/21/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome
Status: Enrolling
Updated:  6/22/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome
Status: Enrolling
Updated: 6/22/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome
Status: Enrolling
Updated:  6/22/2017
Columbia University Medical Center
mi
from
New York, NY
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome
Status: Enrolling
Updated: 6/22/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/22/2017
University of Colorado Cancer Center
mi
from
Denver, CO
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/22/2017
University of Colorado Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  6/22/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 6/22/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer
Status: Enrolling
Updated:  6/22/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer
Status: Enrolling
Updated: 6/22/2017
University of Colorado at Denver Health and Sciences
mi
from
Denver, CO
Click here to add this to my saved trials
Lymphedema in Endometrial Cancer
A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery
Status: Enrolling
Updated:  6/22/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Lymphedema in Endometrial Cancer
A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery
Status: Enrolling
Updated: 6/22/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  6/22/2017
Christiana Care Health Services, Inc
mi
from
Newark, DE
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 6/22/2017
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  6/22/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 6/22/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials